While the general efficacy of A-485 against the large number of tumor cell lines is impressive, none of the lines tested involved CIC-DUX4 fusions, where our data shows that P300 inhibition would specifically inactivate the primary oncogenic driver, leading to a specific toxicity in excess of the generic toxicity of inhibiting HAT activity. The gene discussed is TMPRSS11D; the disease is neoplasm.